DBV Technologies previously announced that it had raised €166.7 million in gross proceeds from the full exercise of warrants ...

Châtillon, France, January 16, 2026DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of ...

DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants DBV sufficiently funded through the expected Biologics License ...

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”) ...

On May 28, Goldman Sachs analyst Rajan Sharma reinstated his sell rating on DBV Technologies S.A. (NASDAQ:DBVT) and set the price target at $7.25. The analyst has a sell rating despite the company ...

Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...